Genetic Engineering and Manufacturing of Hematopoietic Stem Cells

The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiuyan, Rivière, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415326/
https://www.ncbi.nlm.nih.gov/pubmed/28480310
http://dx.doi.org/10.1016/j.omtm.2017.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415326/
https://www.ncbi.nlm.nih.gov/pubmed/28480310
http://dx.doi.org/10.1016/j.omtm.2017.03.003

Ejemplares similares